Skip to content

Study · Measured the body's own peptide · 2026

2 results

Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients.

Shen A, Wang P, Wu B, Fu H, Zeng Y, Zhang C, Wu P, Zhang X, Zhang H, Xu H, Wang L

American journal of translational research15 Jul 2026

PMID42630864 (opens in a new tab)PMCIDPMC13495646 (opens in a new tab)DOI10.62347/ifrp1860 (opens in a new tab)PepBankPUB-42630864
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyMechanism

    In patients with chronic liver failure, dihydroquercetin adjunctive therapy increased serum Humanin expression.

    In plain wordsIn patients with chronic liver failure, dihydroquercetin raised the body's own humanin in blood.

    Peptide
    Humanin
    Outcome
    IncreaseSerum Humanin after DHQ adjunctive therapy
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Liver

    Source sentences

    Summary
    DHQ adjunctive therapy reduced serum circulating mitochondrial DNA levels in patients with CLF, increased serum SOD2 and Humanin expression
    1 context sentence
    Summary · context
    Blood samples from 15 CLF patients and 15 healthy subjects were retrospectively analyzed.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelIn vitro (cells)Mechanism

    In primary hepatocytes from chronic liver failure patients, dihydroquercetin up-regulated Humanin.

    In plain wordsIn liver cells grown in the lab, dihydroquercetin raised natural humanin levels.

    Peptide
    Humanin
    Outcome
    IncreaseHumanin in primary hepatocytes after DHQ
    Study

    humann: not reported in source

    Primary hepatocytes from chronic liver failure patients
    Outcome group
    Mitochondrial function · Liver

    Source sentences

    Summary
    DHQ reduced apoptosis, up-regulated mitochondrial functional markers (SOD2, Humanin)
    1 context sentence
    Summary · context
    Cells were divided into a control group, a plasma group, and a DHQ intervention group.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.